Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1988 Dec 1;168(6):2007–2021. doi: 10.1084/jem.168.6.2007

Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5)

PMCID: PMC2189157  PMID: 3199066

Abstract

TNF induces hemorrhagic necrosis (HN) when injected into skin exposed to bacterial agents but not when injected into normal skin. In this paper, we present several lines of evidence suggesting that TNF requires the fifth component of complement (C5) to induce HN in skin exposed to bacteria. First, mouse strains that do not have C5 did not develop HN after injection of TNF and bacteria into skin. Second, plasma from C5-sufficient mice could correct the defect in these C5- deficient mice. Third, heating at 56 degrees C for 30 min inactivated the capacity of plasma to reconstitute C5-deficient mice. Fourth, CVF, which is known to inactivate complement, abrogated the capability of C5- sufficient mice to respond. Fifth, depleting plasma of hemolytic activity while generating C5a did not affect the capacity of the activated plasma to reconstitute C5-deficient mice. Finally, only the plasma fraction containing molecules of the size range of C5a reconstituted C5-deficient mice. These findings indicate that C5a and not the membrane attack complex is required for HN. Although we do not know through which mechanism C5a participates in the development of HN, we propose that the described HN response is related to a local defense mechanism in which TNF and C5a lead to the disruption of capillaries in the direct vicinity of bacteria. By this mechanism the rapid spread of bacteria or their products into the circulation is prevented. Such a tissue response is consistent with the known higher susceptibility of C5-deficient mice to bacterial infections and provides a model with which to search for the multiple steps involved in this important local defense mechanism.

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bara S., Lint T. F. The third component of complement (C3) bound to tumor target cells enhances their sensitivity to killing by activated macrophages. J Immunol. 1987 Feb 15;138(4):1303–1309. [PubMed] [Google Scholar]
  2. Beutler B., Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 1986 Apr 17;320(6063):584–588. doi: 10.1038/320584a0. [DOI] [PubMed] [Google Scholar]
  3. Beutler B., Greenwald D., Hulmes J. D., Chang M., Pan Y. C., Mathison J., Ulevitch R., Cerami A. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature. 1985 Aug 8;316(6028):552–554. doi: 10.1038/316552a0. [DOI] [PubMed] [Google Scholar]
  4. Beutler B., Mahoney J., Le Trang N., Pekala P., Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med. 1985 May 1;161(5):984–995. doi: 10.1084/jem.161.5.984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  6. CINADER B., DUBISKI S., WARDLAW A. C. DISTRIBUTION, INHERITANCE, AND PROPERTIES OF AN ANTIGEN, MUB1, AND ITS RELATION TO HEMOLYTIC COMPLEMENT. J Exp Med. 1964 Nov 1;120:897–924. doi: 10.1084/jem.120.5.897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666–3670. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cochrane C. G., Müller-Eberhard H. J., Aikin B. S. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol. 1970 Jul;105(1):55–69. [PubMed] [Google Scholar]
  9. ERICKSON R. P., TACHIBANA D. K., HERZENBERG L. A., ROSENBERG L. T. A SINGLE GENE CONTROLLING HEMOLYTIC COMPLEMENT AND A SERUM ANTIGEN IN THE MOUSE. J Immunol. 1964 Apr;92:611–615. [PubMed] [Google Scholar]
  10. Fernandez H. N., Henson P. M., Otani A., Hugli T. E. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol. 1978 Jan;120(1):109–115. [PubMed] [Google Scholar]
  11. Fernandez H. N., Hugli T. E. Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a. J Immunol. 1976 Nov;117(5 Pt 1):1688–1694. [PubMed] [Google Scholar]
  12. Ferreira A., Nussenweig V. Control of C3 levels in mice during ontogeny by a gene in the central region of the H-2 complex. Nature. 1976 Apr 15;260(5552):613–615. doi: 10.1038/260613a0. [DOI] [PubMed] [Google Scholar]
  13. Ferreira A., Nussenzweig V. Genetic linkage between serum levels of the third component of complement and the H-2 complex. J Exp Med. 1975 Feb 1;141(2):513–517. doi: 10.1084/jem.141.2.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fong J. S., Good R. A. Prevention of the localized and generalized Shwartzman reactions by an anticomplementary agent, cobra venom factor. J Exp Med. 1971 Sep 1;134(3 Pt 1):642–655. doi: 10.1084/jem.134.3.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gerard C., Hugli T. E. Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: evidence of a modulator role for the oligosaccharide unit in human des-Arg74-C5a. Proc Natl Acad Sci U S A. 1981 Mar;78(3):1833–1837. doi: 10.1073/pnas.78.3.1833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Havell E. A., Fiers W., North R. J. The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med. 1988 Mar 1;167(3):1067–1085. doi: 10.1084/jem.167.3.1067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hugli T. E., Gerard C., Kawahara M., Scheetz M. E., 2nd, Barton R., Briggs S., Koppel G., Russell S. Isolation of three separate anaphylatoxins from complement-activated human serum. Mol Cell Biochem. 1981 Dec 4;41:59–66. doi: 10.1007/BF00225297. [DOI] [PubMed] [Google Scholar]
  18. Jensen J. Anaphylatoxin in its relation to the complement system. Science. 1967 Mar 3;155(3766):1122–1123. doi: 10.1126/science.155.3766.1122. [DOI] [PubMed] [Google Scholar]
  19. Johnson K. J., Ward P. A. Protective function of C6 in rabbits treated with bacterial endotoxin. J Immunol. 1971 Apr;106(4):1125–1127. [PubMed] [Google Scholar]
  20. Klebanoff S. J., Vadas M. A., Harlan J. M., Sparks L. H., Gamble J. R., Agosti J. M., Waltersdorph A. M. Stimulation of neutrophils by tumor necrosis factor. J Immunol. 1986 Jun 1;136(11):4220–4225. [PubMed] [Google Scholar]
  21. Kramer S. M., Carver M. E. Serum-free in vitro bioassay for the detection of tumor necrosis factor. J Immunol Methods. 1986 Nov 6;93(2):201–206. doi: 10.1016/0022-1759(86)90189-4. [DOI] [PubMed] [Google Scholar]
  22. Müller U., Jongeneel C. V., Nedospasov S. A., Lindahl K. F., Steinmetz M. Tumour necrosis factor and lymphotoxin genes map close to H-2D in the mouse major histocompatibility complex. Nature. 1987 Jan 15;325(6101):265–267. doi: 10.1038/325265a0. [DOI] [PubMed] [Google Scholar]
  23. Nathan C. F. Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J Clin Invest. 1987 Dec;80(6):1550–1560. doi: 10.1172/JCI113241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Old L. J. Tumor necrosis factor (TNF). Science. 1985 Nov 8;230(4726):630–632. doi: 10.1126/science.2413547. [DOI] [PubMed] [Google Scholar]
  25. Ooi Y. M., Colten H. R. Genetic defect in secretion of complement C5 in mice. Nature. 1979 Nov 8;282(5735):207–208. doi: 10.1038/282207a0. [DOI] [PubMed] [Google Scholar]
  26. Polák L., Turk J. L. Suppression of the haemorrhagic component of the Schwartzmann reaction by anti-complement serum. Nature. 1969 Aug 16;223(5207):738–739. doi: 10.1038/223738a0. [DOI] [PubMed] [Google Scholar]
  27. Rosenberg L. T., Tachibana D. K. Mice deficient in C5. Prog Allergy. 1986;39:169–191. [PubMed] [Google Scholar]
  28. Rothstein J. L., Schreiber H. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sci U S A. 1988 Jan;85(2):607–611. doi: 10.1073/pnas.85.2.607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Rouzer C. A., Cerami A. Hypertriglyceridemia associated with Trypanosoma brucei brucei infection in rabbits: role of defective triglyceride removal. Mol Biochem Parasitol. 1980 Oct;2(1):31–38. doi: 10.1016/0166-6851(80)90046-8. [DOI] [PubMed] [Google Scholar]
  30. Shwartzman G. STUDIES ON BACILLUS TYPHOSUS TOXIC SUBSTANCES : I. PHENOMENON OF LOCAL SKIN REACTIVITY TO B. TYPHOSUS CULTURE FILTRATE. J Exp Med. 1928 Jul 31;48(2):247–268. doi: 10.1084/jem.48.2.247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Spies T., Morton C. C., Nedospasov S. A., Fiers W., Pious D., Strominger J. L. Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex. Proc Natl Acad Sci U S A. 1986 Nov;83(22):8699–8702. doi: 10.1073/pnas.83.22.8699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Swerlick R. A., Yancey K. B., Lawley T. J. A direct in vivo comparison of the inflammatory properties of human C5a and C5a des Arg in human skin. J Immunol. 1988 Apr 1;140(7):2376–2381. [PubMed] [Google Scholar]
  33. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., 3rd, Zentella A., Albert J. D. Shock and tissue injury induced by recombinant human cachectin. Science. 1986 Oct 24;234(4775):470–474. doi: 10.1126/science.3764421. [DOI] [PubMed] [Google Scholar]
  34. Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  35. Vogt W. The anaphylatoxin-forming system. Ergeb Physiol. 1967;59:160–184. doi: 10.1007/BF02269143. [DOI] [PubMed] [Google Scholar]
  36. Wheat W. H., Wetsel R., Falus A., Tack B. F., Strunk R. C. The fifth component of complement (C5) in the mouse. Analysis of the molecular basis for deficiency. J Exp Med. 1987 May 1;165(5):1442–1447. doi: 10.1084/jem.165.5.1442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wissler J. H. Chemistry and biology of the anaphylatoxin related serum peptide system. I. Purification, crystallization and properties of classical anaphylatoxin from rat serum. Eur J Immunol. 1972 Feb;2(1):73–83. doi: 10.1002/eji.1830020115. [DOI] [PubMed] [Google Scholar]
  38. van Dijk H., Rademaker P. M., Willers J. M. Estimation of classical pathway of mouse complement activity by use of sensitized rabbit erythrocytes. J Immunol Methods. 1980;39(3):257–268. doi: 10.1016/0022-1759(80)90060-5. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES